Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2017

View Archived Issues

Dendright extends collaboration with Janssen and adds Arthritis Queensland as a partner

Eisai, Chugai and Roche sign agreements for flunitrazepam rights in Japan

Telix and Wilex sign license agreement for Redectane

Bristol-Myers Squibb patents IRAK-4 inhibitors

Sumitomo Dainippon Pharma report compounds for treatment of cancer

European Commission confirms orphan drug designation for TB-403 for medulloblastoma

Team in Portugal describes antimalarial agents

AnaMar reports 5-HT2B receptor antagonists

GlaxoSmithKline patents EZH2 inhibitors for cancer

Pierre Fabre reports Plk-1 inhibitors

177Lu-PSMA-617 demonstrates favorable safety and high efficacy in patients with mCRPC

Results from second pivotal trial of ulipristal acetate for abnormal uterine bleeding

Bivalent Vaxwave vaccine shows in vivo efficacy in models of cytomegalovirus infection

Evotec and MaRS Innovation announce launch of Fibrocor Therapeutics

NRC supports Fedora's development of antimicrobial product candidates

AstraZeneca updates status of durvalumab trials in first-line NSCLC

FDA designates NS-065 an orphan drug for the treatment of Duchenne muscular dystrophy

Horizon Discovery broadens gene-editing capabilities

Audentes Therapeutics gives update on programs at J.P. Morgan meeting

Novogene to acquire Pacific Biosciences' Sequel Systems

CytomX initiates first-in-human study of CX-072 to treat solid tumors and lymphomas

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...